晚年抑郁症艾司西酞普兰联合美金刚或安慰剂治疗反应的全血转录组特征
本研究基于一项双盲随机安慰剂对照试验(NCT01902004),对晚年抑郁症伴主观记忆抱怨患者全血样本进行转录组分析,比较艾司西酞普兰单药与联合美金刚治疗缓解者的基因表达模式。结果显示两组缓解者基线与治疗6个月后基因表达模式不同,单药缓解关联细胞增殖、凋亡和炎症反应,联合缓解关联细胞清除、代谢和细胞骨架动态,两者均调节炎症但效应通路不同。
要点
- 艾司西酞普兰单药与联合美金刚缓解者全血基因表达模式不同。
- 单药缓解关联细胞增殖、凋亡和炎症反应功能。
- 联合缓解关联细胞清除、代谢和细胞骨架动态过程。
核心结论
- 艾司西酞普兰单药与联合美金刚治疗缓解的晚年抑郁症患者呈现独特的全血基因表达模式。
- 两种治疗均调节炎症反应,但通过不同的效应通路实现。
研究设计与样本
- 基于双盲随机安慰剂对照试验(NCT01902004)的全血样本转录组分析。
- 比较艾司西酞普兰单药与艾司西酞普兰联合美金刚治疗缓解者与非缓解者的基因表达谱。
主要发现
- 艾司西酞普兰单药缓解者基线与治疗6个月后基因表达模式独特。
- 艾司西酞普兰联合美金刚缓解者基线与治疗6个月后基因表达模式独特。
- 功能富集分析显示单药缓解关联细胞增殖、凋亡和炎症反应。
- 联合缓解关联细胞清除、代谢和细胞骨架动态。
临床怎么用
- 联合美金刚可能通过细胞清除、代谢和细胞骨架动态相关通路带来认知获益。
- 两种治疗均调节炎症但通路不同,提示需进一步研究以解释联合治疗对认知的优越效应。
局限性
- 需进一步研究以理解这些结果对解释联合治疗长期认知优越效应的意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drugs that target glutamate neuronal transmission, such as memantine, offer a novel approach to the treatment of late-life depression, which is frequently comorbid with cognitive impairment. The results of our recently published double-blind, randomized, placebo-controlled trial of escitalopram or escitalopram/memantine in late-life depression with subjective memory complaints (NCT01902004) indicated no differences between treatments in depression remission, but additional benefits in cognition at 12-month follow-up with combination treatment. To identify pathways and biological functions uniquely induced by combination treatment that may explain cognitive improvements, we generated transcriptional profiles of remission compared with non-remission from whole blood samples. Remitters to escitalopram compared with escitalopram/memantine combination treatment display unique patterns of gene expression at baseline and 6 months after treatment initiation. Functional enrichment analysis demonstrates that escitalopram-based remission associates to functions related to cellular proliferation, apoptosis, and inflammatory response. Escitalopram/memantine-based remission, however, is characterized by processes related to cellular clearance, metabolism, and cytoskeletal dynamics. Both treatments modulate inflammatory responses, albeit via different effector pathways. Additional research is needed to understand the implications of these results in explaining the observed superior effects of combination treatment on cognition observed with prolonged treatment.
引用
- Grzenda A, Siddarth P, Laird KT, et al. Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression. Mol Psychiatry. 2020. PMID: 32382137. doi:10.1038/s41380-020-0752-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。